Interim results for the six months ended 30 Jun 25

AI SummaryClose X

Shield Therapeutics plc announced its unaudited interim results for the six months ended 30 June 2025, reporting a substantial increase in Group revenues to $21.4 million, a 1.8x increase compared to H1 2024 ($12.1 million). ACCRUFeR® revenue was $19.2 million (H1 2024: $11.0 million), with approximately 84,000 prescriptions sold (H1 2024: approximately 65,200). The average net selling price increased to $214 (H1 2024: $158), a 1.4x increase. The Group loss significantly narrowed to $9.5 million (H1 2024: $15.5 million). Cash and cash equivalents increased to $10.8 million (31 December 2024: $6.5 million). The company reported significant progress in global partnerships in Canada, South Korea, China, and Japan, and remains on track to achieve cash flow positivity by the end of 2025. Milestone payments received totalled approximately $887,000.

Disclaimer*

UK 100

Latest directors dealings